-
Mashup Score: 3Durable Transfusion Independence in Lower-Risk MDS - 22 day(s) ago
Gary J. Schiller, MD, reviews recent data on durable transfusion independence for patients with lower-risk MDS in the IMerge phase 3 study and discusses how transfusion frequency affects patient outcomes.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Choosing Treatment for Lower-Risk MDS - 23 day(s) ago
Experts comment on factors that influence their decision-making when treating patients with lower-risk MDS.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Addressing MDS Treatment Gap Post Hypomethylating Failure - 1 month(s) ago
The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Aditi Shastri, MD: Clinicians Needs to ‘Come Together’ on TP53-Mutated MDS | Blood Cancers Today - 1 month(s) ago
Using the VALIDATE database, researchers looked at treatment response to HMAs and overall survival in patients with TP53-mutated MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
This early analysis suggests that the combination of oral decitabine plus cedazuridine with venetoclax for higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia is safe in most patients, with encouraging activity. Longer follow-up will be needed to confirm these data.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2STIMULUS-MDS1 Trial Compares Sabatolimab Plus HMAs Versus Placebo in Higher-Risk MDS | Blood Cancers Today - 2 month(s) ago
Complete response was achieved in 14 patients (22%) in the sabatolimab group, versus 11 patients (18%) in the placebo group.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1What Is the Impact of Luspatercept on the Genomic Landscape in Lower-Risk MDS? | Blood Cancers Today - 2 month(s) ago
Rami Komrokji, MD, discussed the impact of luspatercept on the genomic landscape in patients with lower-risk MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Aditi Shastri, MD: Clinicians Needs to ‘Come Together’ on TP53-Mutated MDS | Blood Cancers Today - 2 month(s) ago
Using the VALIDATE database, researchers looked at treatment response to HMAs and overall survival in patients with TP53-mutated MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Unraveling Communication Challenges in MDS Treatment - 2 month(s) ago
In an interview with Targeted Oncology, Claire Saxton, MBA, and Ashley Moncrief, discussed the importance of education efforts focused on ensuring that patients with MDS understand their diagnosis and options so that they can make informed decisions about their care.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Gary J. Schiller, MD, of @dgsomucla reviews recent data on durable transfusion independence for patients with lower-risk #MDS in the IMerge phase 3 study. https://t.co/VwOyHVBaKe